target directory

brl 101 clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT06300723

Source recordAI-normalized

Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of CRISPR/Cas9-edited Autologous CD34 + Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Severe Sickle Cell Disease

Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of CRISPR/Cas9-edited Autologous CD34 + Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Severe Sickle Cell Disease is a NA clinical asset sponsored by Bioray Laboratories in Sickle Cell Disease. SEO and diligence focus: BRL-101, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI analysis

Indication: Sickle Cell Disease

Modality: small molecule

Target: BRL-101

Sponsor: Bioray Laboratories

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 28, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: BRL-101

View original source fields

Condition raw: Sickle Cell Disease

Condition normalized: Sickle Cell Disease

Modality raw: small molecule

Modality normalized: small molecule

Target raw: BRL-101

Target normalized: BRL-101

Open report

NCT05577312

Source recordAI-normalized

A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia is a PHASE1 clinical asset sponsored by Bioray Laboratories in Beta-Thalassemia. SEO and diligence focus: BRL-101, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.